Payment overview · 2025
General Payments
$331.09
15 reported records · 7 companies
Healthcare provider profile · identity verified
Stanley R Michalski, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Rheumatology · WILLIAMSVILLE, NY · NPI 1386649721
Verified facts
What the public records show
CMS Open Payments records show Stanley R Michalski, M.D. received $331.09 in general payments during 2025 across 15 reported records.
PFIZER INC. accounted for 28.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Benlysta, Enbrel.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RINVOQ as an associated drug or biological on 279238 records involving 34343 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rinvoq by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENBREL as an associated drug or biological on 9330 records involving 2094 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Enbrel by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Prolia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BENLYSTA as an associated drug or biological on 19884 records involving 5034 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Benlysta by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $94.17 | 28.4% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $52.83 | 16.0% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $48.52 | 14.7% | 2 | 2025 |
| BioCryst US Sales Co., LLC | Unresolved — no canonical attribution shown | $41.86 | 12.6% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $39.97 | 12.1% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $31.20 | 9.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $22.54 | 6.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $331.09 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| XELJANZ Normalized: xeljanz |
Drug | PFIZER INC. | $94.17 | 5 | 2025 |
Source payment records
|
|||||
| SAPHNELO Normalized: saphnelo |
Biological | AstraZeneca Pharmaceuticals LP | $52.83 | 2 | 2025 |
Source payment records
|
|||||
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $48.52 | 2 | 2025 |
Source payment records
|
|||||
| ORLADEYO Normalized: orladeyo |
Drug | BioCryst US Sales Co., LLC | $41.86 | 2 | 2025 |
Source payment records
|
|||||
| BENLYSTA Normalized: benlysta |
Biological | GlaxoSmithKline, LLC. | $31.20 | 1 | 2025 |
Source payment records
|
|||||
| ENBREL Normalized: enbrel |
Biological | Amgen Inc. | $23.84 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $23.84 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $22.54 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BENLYSTA benlysta |
2025 | Benlysta | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ENBREL enbrel |
2025 | Enbrel | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | RINVOQ open payments reported associated product |
CMS Open Payments — General Payments 279238 supporting records · 34343 recipient NPIs · example record 1201352600 |
Rinvoq · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | ENBREL open payments reported associated product |
CMS Open Payments — General Payments 9330 supporting records · 2094 recipient NPIs · example record 1226877474 |
Enbrel · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
33 | 20 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | BENLYSTA open payments reported associated product |
CMS Open Payments — General Payments 19884 supporting records · 5034 recipient NPIs · example record 1190332353 |
Benlysta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 486 | 64 |
| Prednisone | Prednisone | 402 | 72 |
| Methotrexate | Methotrexate Sodium | 218 | 52 |
| Lisinopril | Lisinopril | 186 | 43 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 178 | 40 |
| Levothyroxine Sodium | Levothyroxine Sodium | 122 | 29 |
| Amlodipine Besylate | Amlodipine Besylate | 120 | 27 |
| Atorvastatin Calcium | Atorvastatin Calcium | 120 | 33 |
| Omeprazole | Omeprazole | 91 | 25 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 85 | 11 |
| Tramadol Hcl | Tramadol Hcl | 80 | 18 |
| Allopurinol | Allopurinol | 79 | 23 |
| Gabapentin | Gabapentin | 79 | 16 |
| Oxycontin | Oxycodone Hcl | 74 | suppressed |
| Pregabalin | Pregabalin | 72 | 11 |
| Alendronate Sodium | Alendronate Sodium | 71 | 26 |
| Trazodone Hcl | Trazodone Hcl | 68 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 66 | 14 |
| Oxycodone Hcl | Oxycodone Hcl | 62 | suppressed |
| Folic Acid | Folic Acid | 60 | 13 |
| Cevimeline Hcl | Cevimeline Hcl | 56 | 13 |
| Celecoxib | Celecoxib | 54 | suppressed |
| Furosemide | Furosemide | 50 | suppressed |
| Baclofen | Baclofen | 46 | suppressed |
| Metformin Hcl | Metformin Hcl | 46 | 14 |
| Eliquis | Apixaban | 45 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 44 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 44 | suppressed |
| Enbrel Sureclick | Etanercept | 43 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 43 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 42 | suppressed |
| Leflunomide | Leflunomide | 42 | 12 |
| Morphine Sulfate Er | Morphine Sulfate | 41 | suppressed |
| Potassium Chloride | Potassium Chloride | 40 | suppressed |
| Alprazolam | Alprazolam | 38 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 36 | 17 |
| Synthroid | Levothyroxine Sodium | 36 | suppressed |
| Ibuprofen | Ibuprofen | 35 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 33 | suppressed |
| Naproxen | Naproxen | 33 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 33 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 33 | suppressed |
| Prolia | Denosumab | 33 | 20 |
| Diazepam | Diazepam | 31 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 31 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 30 | suppressed |
| Bumetanide | Bumetanide | 29 | suppressed |
| Lorazepam | Lorazepam | 28 | suppressed |
| Losartan Potassium | Losartan Potassium | 28 | suppressed |
| Simvastatin | Simvastatin | 25 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 24 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | suppressed |
| Methylprednisolone | Methylprednisolone | 23 | 11 |
| Sulfasalazine | Sulfasalazine | 22 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Lyrica | Pregabalin | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 19 | 11 |
| Buprenorphine | Buprenorphine | 19 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 19 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 18 | suppressed |
| Ezetimibe | Ezetimibe | 18 | suppressed |
| Famotidine | Famotidine | 18 | suppressed |
| Jardiance | Empagliflozin | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Meloxicam | Meloxicam | 17 | suppressed |
| Orencia Clickject | Abatacept | 16 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 15 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 15 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 15 | suppressed |
| Fentanyl | Fentanyl | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Benlysta | Belimumab | 13 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Dexamethasone | Dexamethasone | 12 | suppressed |
| Enbrel | Etanercept | 12 | suppressed |
| Humalog | Insulin Lispro | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Meprobamate | Meprobamate | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Probenecid-Colchicine | Probenecid/Colchicine | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Topamax | Topiramate | 12 | suppressed |
| Xeljanz Xr | Tofacitinib Citrate | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Orencia | Abatacept/Maltose | 11 | suppressed |
| Remicade | Infliximab | 11 | suppressed |
| Rinvoq | Upadacitinib | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
| Xtampza Er | Oxycodone Myristate | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $331.09 · 15 records | PFIZER INC. | BENLYSTA, Cologuard Collection Kit, ENBREL, ORLADEYO, OTEZLA, SAPHNELO, SKYRIZI, XELJANZ | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Benlysta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error